Company intelligence / Profile preview

Butterfly Medical

Ownership: Private
Development stage: Commercial

Overview

Butterfly Medical has developed a minimally invasive, implantable device for treating benign prostatic hyperplasia. The procedure does not require cutting, burning, or removing tissue and is fully reversible. The company reports strong early results from clinical trials and has received a CE Mark in Europe. In the US, the device remains investigational and is limited to clinical studies.

Therapeutic areas: Men's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Implantable Medical Devices

Partnerships

Butterfly Medical secured funding from the European Innovation Council (EIC), which includes both grant funding and potential equity investment. No major pharmaceutical or biotech partnerships are listed.

Beyond the preview

Go deeper on Butterfly Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butterfly Medical.

Explore the full profile